Stephanie Singer provides practical legal and business advice to entrepreneurs, startups and high-growth companies throughout their lifecycle. She represents a wide range of technology and life sciences companies on formation, equity-related matters, corporate governance, venture capital financings, mergers and acquisitions, and ongoing corporate matters. In addition, she represents venture capital funds in making portfolio investments. Ms. Singer also has considerable experience with public offerings, public company counseling and fund formation. Prior to joining WilmerHale, Ms. Singer worked at Highland Capital Partners and at Entrepreneur magazine.
Learn more about Ms. Singer's practice and how she can support your startup on WilmerHaleLaunch.com.
Ms. Singer regularly presents to students at local universities on startup topics. She is heavily involved with the Jonathan Nelson Center for Entrepreneurship at Brown University, and has also given presentations at Boston University, Suffolk Law School and Harvard Law School. Ms. Singer counsels students through Harvard's Innovation Lab.
Ms. Singer is also involved in Combined Jewish Philanthropies, through the Women's Division and the Lawyers' and Accountants' Division, as well as other community organizations including 100 Women of Needham and her children's schools.
Ms. Singer's pro bono practices focuses primarily on nonprofit organizations. Ms. Singer has assisted multiple charitable organizations in obtaining 501(c)(3) status from the IRS, and she assists nonprofits with ongoing compliance and corporate governance matters. Ms. Singer also assists organizations who have lost their 501(c)(3) status or are otherwise out of compliance regain compliance with federal and state authorities.
- Represented Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, in its Series C financing
- Represented Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, in its Series A financing
- Represented Aquinnah Pharmaceuticals, a biotechnology company focused on RNA binding proteins for neurodegenerative diseases, in a $15 million investment
- Represented Reflexis, a leader in retail real-time execution and workforce management solutions, in a minority equity investment
- Represented SyncOnSet Technologies, a leading entertainment technology company digitizing physical production and managing creative content, in its $1.5 million Series A financing
- Represented Aushon BioSystems, a global provider of protein biomarker measurement and analysis products and services, in its $6.14 million Series C financing
- Represented Syros Pharmaceuticals, a life sciences company, in its IPO
- Represented Accion Systems, a space technology startup led by MIT graduates, in its $7.5 million Series A funding
- Represented Acacia Communications, a leading provider of high-speed coherent optical interconnect products, in its IPO
Insights & News
JD, Harvard Law School, 2010cum laude Editor-in-Chief, The Harvard Negotiation Law Review
AB, Cognitive Science and Judaic Studies, Brown University, 2004magna cum laude Phi Beta Kappa